首页> 美国卫生研究院文献>other >Design and use of mouse control DNA for DNA biomarker extraction and PCR detection from urine: application for transrenal Mycobacterium tuberculosis DNA detection
【2h】

Design and use of mouse control DNA for DNA biomarker extraction and PCR detection from urine: application for transrenal Mycobacterium tuberculosis DNA detection

机译:小鼠对照DNA的设计和用途用于从尿液中提取DNA生物标志物和PCR检测:在经肾结核分枝杆菌DNA检测中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Urine samples are increasingly used for diagnosing infections including Escherichia coli, Ebola virus, and Zika virus. However, extraction and concentration of nucleic acid biomarkers from urine is necessary for many molecular detection strategies such as polymerase chain reaction (PCR). Since urine samples typically have large volumes with dilute biomarker concentrations making them prone to false negatives, another impediment for urine-based diagnostics is the establishment of appropriate controls particularly to rule out false negatives. In this study, a mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH) DNA target was added to retrospectively collected urine samples from tuberculosis (TB)-infected and TB-uninfected patients to indicate extraction of intact DNA and removal of PCR inhibitors from urine samples. We tested this design on surrogate urine samples, retrospective 1 milliliter (mL) urine samples from patients in Lima, Peru and retrospective 5 mL urine samples from patients in Cape Town, South Africa. Extraction/PCR control DNA was detectable in 97% of clinical samples with no statistically significant differences among groups. Despite the inclusion of this control, there was no difference in the amount of TB IS6110 Tr-DNA detected between TB-infected and TB-uninfected groups except for samples from known HIV-infected patients. We found a increase in TB IS6110 Tr-DNA between TB/HIV co-infected patients compared to TB-uninfected/HIV-infected patients (N=18, p=0.037). The inclusion of an extraction/PCR control DNA to indicate successful DNA extraction and removal of PCR inhibitors should be easily adaptable as a sample preparation control for other acellular sample types.
机译:尿液样本越来越多地用于诊断包括大肠杆菌,埃博拉病毒和寨卡病毒在内的感染。但是,对于许多分子检测策略(例如聚合酶链反应(PCR)),从尿液中提取和浓缩核酸生物标记物是必需的。由于尿液样本通常具有大量的生物标志物浓度,使它们易于产生假阴性,因此基于尿液的诊断的另一个障碍是建立适当的对照,尤其是要排除假阴性。在这项研究中,将小鼠甘油醛3-磷酸脱氢酶(GAPDH)DNA靶标添加到了从结核病(TB)感染和未感染TB的患者中回顾性收集的尿液样本中,以指示完整DNA的提取和PCR抑制剂从尿液样本中的去除。我们在替代尿液样本,秘鲁利马患者的回顾性1毫升(mL)尿液样本以及南非开普敦患者的回顾性5毫升尿液样本中测试了该设计。提取/ PCR对照DNA可在97%的临床样品中检测到,各组之间无统计学差异。尽管包括了该对照,但是除了来自已知HIV感染患者的样本外,在TB感染组和未感染TB组之间检测到的TB IS6110 Tr-DNA的量没有差异。我们发现与未感染结核病/ HIV感染的患者相比,合并结核病/ HIV的患者之间的结核病IS6110 Tr-DNA增加(N = 18,p = 0.037)。包括提取/ PCR对照DNA的指示DNA的成功提取和PCR抑制剂的去除应该很容易适应作为其他非细胞样品类型的样品制备对照。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号